|
Myobloc® (rimabotulinumtoxinB) Injection and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution represent the only type B toxin currently available to physicians and patients worldwide.
Important Safety Information
WARNING: Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses. (See WARNINGS, PRECAUTIONS, and OVERDOSE sections of full Prescribing Information).
MYOBLOC and NeuroBloc are indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and pain associated with cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.
Before administering MYOBLOC, physicians should consult the Important Safety Information, full Prescribing Information and Medication Guide. (See WARNINGS, PRECAUTIONS, and OVERDOSE sections of full Prescribing Information)
MYOBLOC and NeuroBloc are delivered as a premixed solution in three ready-to-use vial sizes with no reconstitution necessary.
Authorized U.S. Distributors
|